Who is eligible for clinical trial NCT05206877?

Participants must meet the protocol's inclusion criteria for Glaucoma. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT05206877 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-11-23

Topical Insulin for Glaucoma (NCT05206877)

Topical Insulin for Glaucoma and Optic Neuropathies

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Stanford University

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (7 items).

Location: Byers Eye Institute at Stanford University — Palo Alto, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Capable to provide informed consent
Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.
Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Pregnant or breastfeeding woman
Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)
Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus
Inability to perform reliable visual field
Unable to provide informed consent
Unable to complete the tests and follow-ups required by the study

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Byers Eye Institute at Stanford University — Palo Alto, California

📞 Contact the Study Coordinator

Phone: (650) 497-7846

Email: mnunez1@stanford.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Glaucoma

Change in IOP Fluctuation After DSLT — Fort Worth, Texas
Optic Nerve Head Strain in Non-glaucoma Subjects — Baltimore, Maryland
Novel Glaucoma Diagnostics — Philadelphia, Pennsylvania
This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling. — Montreal, Quebec
Glaucoma Laser Assessment of Stability and Sustainability — Coon Rapids, Minnesota
Novel Markers for Detecting Early Progression of Glaucoma — Halifax, Nova Scotia

Explore by condition: All Glaucoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗